The Patent Finder

AutoImmune Inc.

Also on record
Records under this name other than patents AutoImmune Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to AutoImmune Inc.

PatentTitleStatus Expires Confidence
US 6,019,971Treatment of autoimmune arthritis by oral administration of collagen
Formerly held
Term ended
Term ended Feb 1, 2017 · From the USPTO record
Term endedTerm ended Feb 1, 2017From the USPTO record
US 6,077,509Peptide fragments of myelin basic protein
Lapsed on the fee record
Ended Jun 20, 2012 · From the USPTO record
Lapsed on the fee recordEnded Jun 20, 2012From the USPTO record
US 6,039,947Peptides derived from immunodominant epitopes of myelin basic protein
Lapsed on the fee record
Ended Mar 21, 2012 · From the USPTO record
Lapsed on the fee recordEnded Mar 21, 2012From the USPTO record
US 6,036,957Suppression of T-cell proliferation using peptide fragments of myelin basic protein
Lapsed on the fee record
Ended Mar 14, 2012 · From the USPTO record
Lapsed on the fee recordEnded Mar 14, 2012From the USPTO record
US 6,645,504Bystander suppression of type I diabetes by oral administration of glucagon
Lapsed on the fee record
Ended Nov 11, 2011 · From the USPTO record
Lapsed on the fee recordEnded Nov 11, 2011From the USPTO record
US 6,703,361Method of treating or preventing Type 1 diabetes by oral administration of insulin
Term ended
Ended no later than Nov 11, 2010 · From the USPTO record
Term endedEnded no later than Nov 11, 2010From the USPTO record
US 5,399,347Method of treating rheumatoid arthritis with type II collagen
Formerly held
Term ended
Term ended no later than Mar 21, 2015 · Low confidence
Term endedTerm ended no later than Mar 21, 2015Low confidence
US 5,571,499Treatment of autoimmune diseases by aerosol administration of autoantigens
Formerly held
Term ended
Term ended no later than Nov 5, 2016 · Low confidence
Term endedTerm ended no later than Nov 5, 2016Low confidence
US 5,571,500Treatment of autoimmune diseases through administration by inhalation of autoantigens
Formerly held
Term ended
Term ended no later than Nov 5, 2016 · Low confidence
Term endedTerm ended no later than Nov 5, 2016Low confidence
US 5,593,698Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
Term ended
Term ended no later than Jan 14, 2017 · Low confidence
Term endedTerm ended no later than Jan 14, 2017Low confidence
10 of 33 patents shown.
Pro members see all 33.
Pro members: see all 33 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited